MxA polymorphisms are associated with risk and age-at-onset in Alzheimer disease and accelerated cognitive decline in

Suk Ling Ma1, Wei Huang, Nelson L S Tang

  • 1Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong .

Rejuvenation Research
|September 7, 2012
PubMed

Insights

Genetic variations in the myxovirus resistance protein 1 (MxA) gene are linked to Alzheimer disease (AD) risk, age of onset, and cognitive decline. This study highlights MxA

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Alzheimer disease (AD) is a leading neurodegenerative disorder where inflammation plays a key role in its pathogenesis.
  • Myxovirus resistance protein 1 (MxA), an interferon-induced protein, has been observed in AD brain senile plaques, suggesting its potential involvement in AD development.

Purpose of the Study:

  • To investigate the association between myxovirus resistance protein 1 (MxA) gene single-nucleotide polymorphisms (SNPs) and the predisposition, age of onset (AAO), and cognitive deterioration rate in Alzheimer disease (AD).

Main Methods:

  • Genotyping of 12 MxA SNPs in 220 AD patients and 316 healthy controls.
  • Longitudinal follow-up of healthy subjects for 2 years to assess cognitive decline.
  • Functional assays to evaluate MxA expression in relation to specific haplotypes.

Main Results:

  • Two MxA SNPs (rs17000900 and rs461093) were significantly associated with AD risk.
  • Six MxA SNPs, including MxA -123, correlated with the age of onset (AAO) of AD.
  • Carriers of minor alleles in five MxA SNPs showed faster cognitive decline over two years.
  • A functional assay confirmed increased MxA expression linked to the -123A/-88T haplotype.

Conclusions:

  • This study provides the first evidence linking MxA gene polymorphisms to Alzheimer disease (AD) predisposition.
  • MxA SNPs significantly modulate the age of onset (AAO) and the rate of cognitive decline in AD patients.
  • MxA genetic variations represent potential biomarkers for AD risk and progression.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
190
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.5K